News > Press Release
Alzheimer's Disease Research
Mourning the Loss of Award-Winning Neuropathologist Donald L. Price, MD
BrightFocus Editorial Staff
The following message was issued from BrightFocus Foundation’s President and CEO, Stacy Pagos Haller:
BrightFocus Foundation joins the Alzheimer’s disease research community in paying tribute to a world-renowned neuropathologist who recently passed away, Donald L. Price, MD, Johns Hopkins University.
Don was a true pioneer in Alzheimer’s research and changed the way we understand the disease, particularly at a molecular level.
We were fortunate to work with Don our Scientific Review Committee for 11 years, serving as a co-chair from 1993 to 2000. We are also proud to have supported his innovative research.
On behalf of BrightFocus, I extend our deepest sympathy to Dr. Price’s family, his colleagues at Johns Hopkins University, and the myriad scientists he helped guide over the years. He leaves an incredible legacy which will carry on for generations.
Read more:
Immunocytochemical Evaluation of Hippocampal Pathology in AD (ADR Grant)
Cholinergic Systems in Models of Alzheimer’s Disease (ADR Grant)
Cellular and Molecular Studies of Beta-Amyloid in Aging and AD (ADR Grant)
About BrightFocus Foundation
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Through its flagship research programs — Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research— the Foundation has awarded nearly $300 million in groundbreaking research funding over the past 51 years and shares the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
News
Related Articles and Information
Press Release
BrightFocus Foundation Receives $3.2 Million Grant for Alzheimer’s Research
BrightFocus Foundation received a $3.2 million grant from an anonymous foundation to support 12 new Alzheimer’s Disease Research grants.
Press Release
Investment in Alzheimer’s Research Today Will Yield Health Benefits for the Next Generation of Adults With Down Syndrome, New Report Finds
Report shows that boosting research investment into the wellbeing of adults with Down syndrome would improve their quality-of-life outcomes, reduce caregiving costs, and extend the lifespan of adults with Down syndrome by five years.
Article
FDA Approves Eli Lilly’s Alzheimer’s Treatment
Another disease-modifying Alzheimer's therapy hits the market.
Article
Upcoming Alzheimer’s Drug Receives Unanimous Support from FDA Advisory Committee
An FDA decision on Eli Lilly's donanemab is expected in the coming months.
